Sarepta Therapeutics, Inc.

NasdaqGS:SRPT Stock Report

Market Cap: US$12.2b

Sarepta Therapeutics Future Growth

Future criteria checks 5/6

Sarepta Therapeutics is forecast to grow earnings and revenue by 41.9% and 19.6% per annum respectively. EPS is expected to grow by 42.1% per annum. Return on equity is forecast to be 48.1% in 3 years.

Key information

41.9%

Earnings growth rate

42.1%

EPS growth rate

Biotechs earnings growth20.6%
Revenue growth rate19.6%
Future return on equity48.1%
Analyst coverage

Good

Last updated22 Mar 2024

Recent future growth updates

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Mar 02
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Recent updates

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Mar 02
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Shares Fly 29% But Investors Aren't Buying For Growth

Feb 06
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Shares Fly 29% But Investors Aren't Buying For Growth

Sarepta Therapeutics: Navigating Elevidys Towards FDA Approval

Jan 22

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Shares Could Be 50% Below Their Intrinsic Value Estimate

Jan 10
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Shares Could Be 50% Below Their Intrinsic Value Estimate

There's No Escaping Sarepta Therapeutics, Inc.'s (NASDAQ:SRPT) Muted Revenues

Dec 20
There's No Escaping Sarepta Therapeutics, Inc.'s (NASDAQ:SRPT) Muted Revenues

Does Sarepta Therapeutics (NASDAQ:SRPT) Have A Healthy Balance Sheet?

Nov 29
Does Sarepta Therapeutics (NASDAQ:SRPT) Have A Healthy Balance Sheet?

Is Sarepta Therapeutics (NASDAQ:SRPT) Using Too Much Debt?

Aug 08
Is Sarepta Therapeutics (NASDAQ:SRPT) Using Too Much Debt?

Is Sarepta Therapeutics (NASDAQ:SRPT) Using Too Much Debt?

Apr 30
Is Sarepta Therapeutics (NASDAQ:SRPT) Using Too Much Debt?

Is Sarepta Therapeutics (NASDAQ:SRPT) Weighed On By Its Debt Load?

Jan 17
Is Sarepta Therapeutics (NASDAQ:SRPT) Weighed On By Its Debt Load?

Sarepta Therapeutics seeks FDA accelerated approval for muscle wasting therapy SRP-9001

Sep 29

Sarepta Therapeutics announces offering of $1B of convertible senior notes due 2027

Sep 12

Sarepta says FDA lifted clinical hold on Duchenne candidate

Sep 06

Is Sarepta Therapeutics (NASDAQ:SRPT) Weighed On By Its Debt Load?

Aug 22
Is Sarepta Therapeutics (NASDAQ:SRPT) Weighed On By Its Debt Load?

Sarepta inks licensing deal with Broad Institute for certain adeno-associated viruses

Aug 08

Sarepta stock soars 19% on plans for US filing for gene therapy for neuromuscular disorder

Jul 29

Sarepta Therapeutics (NASDAQ:SRPT) Has Debt But No Earnings; Should You Worry?

May 09
Sarepta Therapeutics (NASDAQ:SRPT) Has Debt But No Earnings; Should You Worry?

Sarepta: The DMD Leader

Apr 26

Sarepta: Still A Solid Long-Term Bet On Sales And Next Generation Treatments

Feb 09

Is Sarepta Therapeutics (NASDAQ:SRPT) Using Debt In A Risky Way?

Feb 07
Is Sarepta Therapeutics (NASDAQ:SRPT) Using Debt In A Risky Way?

A Look At The Intrinsic Value Of Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Dec 06
A Look At The Intrinsic Value Of Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Sarepta: Revenue Keeps Rising While We Wait For Functional Data

Nov 01

Health Check: How Prudently Does Sarepta Therapeutics (NASDAQ:SRPT) Use Debt?

Nov 01
Health Check: How Prudently Does Sarepta Therapeutics (NASDAQ:SRPT) Use Debt?

Is Sarepta Therapeutics (NASDAQ:SRPT) A Risky Investment?

Jul 19
Is Sarepta Therapeutics (NASDAQ:SRPT) A Risky Investment?

Sarepta Therapeutics: Faultlines May Run Deeper Than Assumed

Jun 02

Most Shareholders Will Probably Agree With Sarepta Therapeutics, Inc.'s (NASDAQ:SRPT) CEO Compensation

May 27
Most Shareholders Will Probably Agree With Sarepta Therapeutics, Inc.'s (NASDAQ:SRPT) CEO Compensation

Sarepta Therapeutics EPS beats by $0.03, beats on revenue

May 05

Earnings and Revenue Growth Forecasts

NasdaqGS:SRPT - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/20263,3331,295N/A1,06412
12/31/20252,9471,08050571718
12/31/20241,82122272914619
12/31/20231,243-536-486-501N/A
9/30/20231,105-691-512-539N/A
6/30/20231,003-908-431-489N/A
3/31/2023976-1,115-468-434N/A
12/31/2022933-703-358-325N/A
9/30/2022876-716-289-262N/A
6/30/2022835-507-348-322N/A
3/31/2022766-357-285-364N/A
12/31/2021702-419-382-443N/A
9/30/2021646-486-551-588N/A
6/30/2021600-634-681-702N/A
3/31/2021573-704-795-701N/A
12/31/2020540-554133107N/A
9/30/2020495-601155118N/A
6/30/2020450-530342289N/A
3/31/2020407-656373318N/A
12/31/2019381-715-516-456N/A
9/30/2019365-620-478-415N/A
6/30/2019345-570-536-461N/A
3/31/2019323-403-567-499N/A
12/31/2018301-362-450-389N/A
9/30/2018274-245-345-297N/A
6/30/2018241-216-277-242N/A
3/31/2018203-170-238-210N/A
12/31/2017155-51-128-232N/A
9/30/2017103-115N/A-282N/A
6/30/201757-124N/A-285N/A
3/31/201722-123N/A-243N/A
12/31/20165-267N/A-246N/A
9/30/20161-243N/A-196N/A
6/30/20161-239N/A-182N/A
3/31/20161-218N/A-167N/A
12/31/20151-220N/A-149N/A
9/30/20150-200N/A-144N/A
6/30/20151-177N/A-133N/A
3/31/20154-169N/A-144N/A
12/31/201410-136N/A-129N/A
9/30/201412-100N/A-121N/A
6/30/201415-113N/A-105N/A
3/31/201416-98N/A-78N/A
12/31/201314-112N/A-65N/A
9/30/201319-165N/A-54N/A
6/30/201322-173N/A-42N/A
3/31/201331-146N/A-36N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: SRPT is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.3%).

Earnings vs Market: SRPT is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: SRPT is expected to become profitable in the next 3 years.

Revenue vs Market: SRPT's revenue (19.6% per year) is forecast to grow faster than the US market (8.2% per year).

High Growth Revenue: SRPT's revenue (19.6% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: SRPT's Return on Equity is forecast to be very high in 3 years time (48.1%).


Discover growth companies

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.